nach oben

Erschienen in:

01.02.2013 | Epidemiology

CD24 polymorphisms in breast cancer: impact on prognosis and risk

verfasst von: Katharina Buck, Sarah Hug, Petra Seibold, Irmgard Ferschke, Peter Altevogt, Christof Sohn, Andreas Schneeweiss, Barbara Burwinkel, Dirk Jäger, Dieter Flesch-Janys, Jenny Chang-Claude, Frederik Marmé

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Overexpression of CD24 has a negative impact on breast cancer prognosis. We have recently reported that the CD24 codon 57 Val/Val genotype (rs52812045) is associated with pathologic complete response after neoadjuvant chemotherapy for primary breast cancer and correlates with intratumoral lymphocyte infiltrates. This study was performed to investigate the influence of CD24 polymorphisms on breast cancer prognosis and risk. A total of 2,514 patients and 4,858 controls recruited as part of the MARIE study, a population-based case–control study, were genotyped for two CD24 polymorphisms (rs52812045, rs3838646) using TaqMan custom genotyping assays. Associations with overall and breast cancer-specific survival were assessed using uni- and multivariable Cox regression models stratified by age at diagnosis and adjusted for prognostic factors. Conditional logistic regression analysis adjusted for major risk factors was used to estimate multivariable odds ratios for risk of putative allele carriers compared to wildtype carriers. CD24 Ala/Val was significantly associated with breast cancer prognosis [Val/Val hazard ratio (HR)_adjusted = 1.52; 95 % confidence interval (CI): 1.00–2.30, p = 0.05 and HR_adjusted = 1.83; 95 % CI: 1.10–3.05, p = 0.018 for all-cause and breast cancer-specific mortality, respectively). The association was significant only in patients with a BMI <25 and in those who received adjuvant chemotherapy. None of the CD24 alleles was associated with breast cancer risk. These results provide further evidence of the CD24 Val/Val genotype influencing outcome in primary breast cancer. Together with previous data of CD24 overexpression as a poor prognostic marker, the findings underline the biological importance of CD24 for breast cancer.

Nur mit Berechtigung zugänglich

Aigner S, Ramos CL, Hafezi-moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K (1998) CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 12:1241–1251PubMed

Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P (1997) CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89:3385–3395PubMed

Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andre F, Tursz T, Kroemer G, Zitvogel L (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220:47–59. doi:10.1111/j.1600-065X.2007.00573.x PubMedCrossRef

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059. doi:10.1038/nm1622 PubMedCrossRef

Askew D, Harding CV (2008) Antigen processing and CD24 expression determine antigen presentation by splenic CD4+ and CD8+ dendritic cells. Immunology 123:447–455. doi:10.1111/j.1365-2567.2007.02711.x PubMedCrossRef

Bai XF, Li O, Zhou Q, Zhang H, Joshi PS, Zheng X, Liu Y, Wang Y, Zheng P (2004) CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J Exp Med 200:447–458. doi:10.1084/jem.20040131 PubMedCrossRef

Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65:10783–10793PubMedCrossRef

Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G, Altevogt P (2012) CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis 29:27–38. doi:10.1007/s10585-011-9426-4 PubMedCrossRef

Bretz NP, Salnikov AV, Perne C, Keller S, Wang X, Mierke CT, Fogel M, Erbe-Hofmann N, Schlange T, Moldenhauer G, Altevogt P (2012) CD24 controls Src/STAT3 activity in human tumors. Cell Mol Life Sci. doi:10.1007/s00018-012-1055-9 PubMed

10.

Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Van ‘t Veer LJ, de Groot R, Smit VTHBM, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Orsted DD, Kaur-Knudsen D, Milne RL, Perez JIA, Zamora P, Rodriguez PM, Benitez J, Brauch H, Justenhoven C, Ko YD, Hamann U, Fischer HP, Bruning T, Pesch B, Chang-Claude J, Wang-Gohrke S, Bremer M, Karstens JH, Hillemanns P, Dork T, Nevanlinna HA, Heikkinen T, Heikkila P, Blomqvist C, Aittomaki K, Aaltonen K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kauppinen JM, Kataja V, Auvinen P, Eskelinen M, Soini Y, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Holland H, Lambrechts D, Claes B, Vandorpe T, Neven P, Wildiers H, Flesch-Janys D, Hein R, Loning T, Kosel M, Fredericksen ZS, Wang X, Giles GG, Baglietto L, Severi G, McLean C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Grenaker Alnaes G, Kristensen V, Borresen-Dale AL, Hunter DJ, Hankinson SE, Andrulis IL, Marie Mulligan A, O’Malley FP, Devilee P, Huijts PEA, Tollenaar RAEM, Van Asperen CJ, et al (2011) Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20:3289–3303. doi:10.1093/hmg/ddr228

11.

Buck K, Zaineddin AK, Vrieling A, Heinz J, Linseisen J, Flesch-Janys D, Chang-Claude J (2011) Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 105:1151–1157. doi:10.1038/bjc.2011.374 PubMedCrossRef

12.

Carl JW Jr, Liu JQ, Joshi PS, El-Omrani HY, Yin L, Zheng X, Whitacre CC, Liu Y, Bai XF (2008) Autoreactive T cells escape clonal deletion in the thymus by a CD24-dependent pathway. J Immunol 181:320–328PubMed

13.

Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2009) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. doi:10.1200/JCO.2009.23.7370 PubMed

14.

Fasching PA, Ekici AB, Adamietz B (2011) Breast cancer risk—genes, environment, and clinical practice. Geburtsh Frauenheilk 71:1056–1066. doi:10.1055/s-0031-1280437 CrossRef

15.

Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van ‘t Veer LJ, Udo R, Dunning AM, Greco D, Aittomaki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis I, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dork T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olsen JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John E, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G, Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Arias Perez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK (2012) The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet. doi:10.1093/hmg/dds159

16.

Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123:933–941. doi:10.1002/ijc.23655 PubMedCrossRef

17.

Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P, Sthoeger ZM (1999) CD24 is a marker for human breast carcinoma. Cancer Lett 143:87–94PubMedCrossRef

18.

Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445. doi:10.1146/annurev-immunol-031210-101322 PubMedCrossRef

19.

Hemminki K, Liu X, Ji J, Forsti A, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol 127:180–185. doi:10.1016/j.ygyno.2012.07.100 PubMedCrossRef

20.

Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A (2008) Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 26:1024–1031. doi:10.1080/07357900802098165 PubMedCrossRef

21.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132. doi:10.1200/JCO.2006.10.3523 PubMedCrossRef

22.

Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870–874. doi:10.1038/ng2075 PubMedCrossRef

23.

Jacob J, Bellach J, Grutzmann R, Alldinger I, Pilarsky C, Dietel M, Kristiansen G (2004) Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 4:454–460PubMedCrossRef

24.

Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S (2002) CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161:1215–1221PubMedCrossRef

25.

Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M (2004) CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58:183–192PubMedCrossRef

26.

Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I (2003) CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88:231–236PubMedCrossRef

27.

Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9:4906–4913PubMed

28.

Li D, Zheng L, Jin L, Zhou Y, Li H, Fu J, Shi M, Du P, Wang L, Wu H, Chen GY, Zheng P, Liu Y, Wang FS, Wang S (2009) CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology. doi:10.1002/hep.23047

29.

Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281. doi:10.1200/JCO.2007.14.4147 PubMedCrossRef

30.

Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. doi:10.1007/s10549-011-1647-3

31.

Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R, Gu F, Fu L (2012) Peritumoral FOXP3(+) regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3(+) regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat. doi:10.1007/s10549-012-2132-3

32.

Liu Y, Zheng P (2007) CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol 28:315–320. doi:10.1016/j.it.2007.05.001 PubMedCrossRef

33.

Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132:545–553. doi:10.1007/s10549-011-1620-1 PubMedCrossRef

34.

Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, Ellis IO, Green AR (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955. doi:10.1200/jco.2010.30.5037 PubMedCrossRef

35.

Marme F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sanchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A (2012) CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res Treat 132:819–831. doi:10.1007/s10549-011-1759-9 PubMedCrossRef

36.

Otaegui D, Saenz A, Camano P, Blazquez L, Goicoechea M, Ruiz-Martinez J, Olaskoaga J, Emparanza JA, Lopez de Munain A (2006) CD24V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population. Mult Scler 12:511–514PubMedCrossRef

37.

Ronaghi M, Vallian S, Etemadifar M (2009) CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population. Psychiatry Res. doi:10.1016/j.psychres.2009.01.002 PubMed

38.

Rueda B, Miranda-Filloy JA, Martin J, Gonzalez-Gay MA (2008) Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 35:850–854PubMed

39.

Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N (2008) Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 68:2803–2812. doi:10.1158/0008-5472.CAN-07-6463 PubMedCrossRef

40.

Sanchez E, Abelson AK, Sabio JM, Gonzalez-Gay MA, Ortego-Centeno N, Jimenez-Alonso J, de Ramon E, Sanchez-Roman J, Lopez-Nevot MA, Gunnarsson I, Svenungsson E, Sturfelt G, Truedsson L, Jonsen A, Gonzalez-Escribano MF, Witte T, Alarcon-Riquelme ME, Martin J (2007) Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis Rheum 56:3080–3086. doi:10.1002/art.22871 PubMedCrossRef

41.

Schabath H, Runz S, Joumaa S, Altevogt P (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119:314–325PubMedCrossRef

42.

Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. doi:10.1038/nrendo.2012.114 PubMed

43.

Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomaki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Muller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, Swann R, Dwek M, Perkins A, Milne RL, Benitez J, Zamora MP, Perez JI, Bojesen SE, Nielsen SF, Nordestgaard BG, Flyger H, Guenel P, Truong T, Menegaux F, Cordina-Duverger E, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin MJ, Peto J, Johnson N, Fletcher O, Dos Santos Silva I, Fasching PA, Beckmann MW, Hartmann A, Ekici AB, Lophatananon A, Muir K, Puttawibul P, Wiangnon S, Schmidt MK, Broeks A, Braaf LM, Rosenberg EH, Hopper JL, Apicella C, Park DJ, Southey MC, Swerdlow AJ, Ashworth A, Orr N, Schoemaker MJ, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Shen CY, Yu JC, Hsu HM, Hsiung CN, Hamann U, Dunnebier T, Rudiger T, Ulmer HU, Pharoah PP, Dunning AM, Humphreys MK, Wang Q, Cox A, et al (2012) 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 72:1795–1803. doi:10.1158/0008-5472.CAN-11-3364

44.

Surowiak P, Materna V, Klak K, Spaczynski M, Dietel M, Kristiansen G, Lage H, Zabel M (2005) Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients. Pol J Pathol 56:69–74PubMed

45.

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G (2009) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. doi:10.1038/onc.2009.356 PubMed

46.

Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu RH, Guinther N, Lima J, Zhou Q, Wang T, Zheng X, Birmingham DJ, Rovin BH, Hebert LA, Wu Y, Lynn DJ, Cooke G, Yu CY, Zheng P, Liu Y (2007) A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet 3:e49PubMedCrossRef

47.

Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G (2005) Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 11:6574–6581PubMedCrossRef

48.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13:R126. doi:10.1186/bcr3072 PubMedCrossRef

49.

Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T, Langner C (2007) CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch 450:59–64PubMedCrossRef

50.

Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, Kanomata N, Kawaguchi A, Akiba J, Naito Y, Ohshima K, Yano H (2012) Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. doi:10.1016/j.humpath.2011.12.013

51.

Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J (2009) CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 15:5518–5527. doi:10.1158/1078-0432.CCR-09-0151 PubMedCrossRef

52.

Zhou Q, Rammohan K, Lin S, Robinson N, Li O, Liu X, X-f Bai, Yin L, Scarberry B, Du P, You M, Guan K, Zheng P, Liu Y (2003) CD24 is a genetic modifier for risk and progression of multiple sclerosis. PNAS 100:15041–15046PubMedCrossRef

53.

Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991–2001. doi:10.1172/JCI35180 PubMedCrossRef

Titel: CD24 polymorphisms in breast cancer: impact on prognosis and risk
verfasst von: Katharina Buck
Sarah Hug
Petra Seibold
Irmgard Ferschke
Peter Altevogt
Christof Sohn
Andreas Schneeweiss
Barbara Burwinkel
Dirk Jäger
Dieter Flesch-Janys
Jenny Chang-Claude
Frederik Marmé
Publikationsdatum: 01.02.2013
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2325-9

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

CD24 polymorphisms in breast cancer: impact on prognosis and risk

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast

Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer

Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer

Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie